ArticleDiscover oncology2026
A bibliometric analysis of extrachromosomal DNA in cancer over six decades.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Extrachromosomal DNA (ecDNA) is a critical driver of oncogene amplification and has significantly advanced the understanding of tumor heterogeneity. Although the biological mechanisms and clinical significance of ecDNA have been extensively studied, few articles have systematically summarized the historical development of this field. This study conducted a comprehensive retrospective analysis to map the evolutionary trajectory and research hotspots of ecDNA research in cancer from 1965 to 2025. We retrieved 3,328 publications from the Web of Science Core Collection and Scopus. We analyzed the co-authorship coverage alongside co-citation and co-occurrence of regions, institutions, authors, and keywords using VOSviewer and CiteSpace. The United States and China acted as the predominant global contributors, accounting for 38.25% and 25.81% of publications, respectively. Keyword co-occurrence and burst detection analyses revealed the thematic evolution of the field. Early dominant terms such as "gene amplification" focused on copy number variation in the linear genome without in-depth structural exploration. Contemporary research has shifted to terms including "circular DNA", "chromatin topology", and "drug resistance". This evolution signifies a paradigm shift from linear genome investigations to epigenetic mechanisms and clinical applications. We also discussed development prospects and key challenges while proposing potential solutions to major obstacles. This study aims to provide novel perspectives for advancing ecDNA research and its clinical translation in precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.